Compare Stocks: CVM, DTSQ, KLRS, and ATRA

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ATRA Atara Biotherapeutics	$8.98 -2.4%	$9.27	$3.92 ▼ $19.15	$90.14M	0.12	713,150 shs	22,613 shs
CVM Cel-Sci	$1.59 +1.9%	$1.31	$0.89 ▼ $12.68	$27.79M	0.63	262,815 shs	44,509 shs
DTSQ DT Cloud Star Acquisition	$11.35 +0.2%	$11.33	$10.45 ▼ $12.90	$101.02M	-0.01	3,656 shs	158 shs
KLRS Kalaris Therapeutics	$3.99 -1.0%	$4.17	$3.03 ▼ $11.88	$95.00M	0.2	144,208 shs	16,269 shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ATRA Atara Biotherapeutics	0.00%	-5.15%	+9.79%	-10.51%	-23.65%
CVM Cel-Sci	0.00%	+9.86%	+34.48%	+5.41%	-85.04%
DTSQ DT Cloud Star Acquisition	0.00%	-0.53%	+0.04%	+0.49%	+8.52%
KLRS Kalaris Therapeutics	0.00%	-2.89%	+14.81%	-17.76%	-1.23%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ATRA Atara Biotherapeutics	$8.98 -2.4%	$9.27	$3.92 ▼ $19.15	$90.14M	0.12	713,150 shs	22,613 shs
CVM Cel-Sci	$1.59 +1.9%	$1.31	$0.89 ▼ $12.68	$27.79M	0.63	262,815 shs	44,509 shs
DTSQ DT Cloud Star Acquisition	$11.35 +0.2%	$11.33	$10.45 ▼ $12.90	$101.02M	-0.01	3,656 shs	158 shs
KLRS Kalaris Therapeutics	$3.99 -1.0%	$4.17	$3.03 ▼ $11.88	$95.00M	0.2	144,208 shs	16,269 shs

The Best Nuclear Energy Stocks to Buy

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ATRA Atara Biotherapeutics	0.00%	-5.15%	+9.79%	-10.51%	-23.65%
CVM Cel-Sci	0.00%	+9.86%	+34.48%	+5.41%	-85.04%
DTSQ DT Cloud Star Acquisition	0.00%	-0.53%	+0.04%	+0.49%	+8.52%
KLRS Kalaris Therapeutics	0.00%	-2.89%	+14.81%	-17.76%	-1.23%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ATRA Atara Biotherapeutics	2.50	Moderate Buy	$9.50	5.79% Upside
CVM Cel-Sci	0.00	N/A	N/A	N/A
DTSQ DT Cloud Star Acquisition	2.00	Hold	N/A	N/A
KLRS Kalaris Therapeutics	2.88	Moderate Buy	$18.75	369.92% Upside

Current Analyst Ratings Breakdown

Latest CVM, DTSQ, KLRS, and ATRA Analyst Ratings

Date	Company	Brokerage	Action	Rating
8/24/2026	ATRA Atara Biotherapeutics	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
8/18/2026	ATRA Atara Biotherapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
7/31/2026	ATRA Atara Biotherapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
7/28/2026	KLRS Kalaris Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
7/15/2026	ATRA Atara Biotherapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
7/13/2026	DTSQ DT Cloud Star Acquisition	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (D+) ➝ Hold (C-)
7/7/2026	KLRS Kalaris Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
6/29/2026	DTSQ DT Cloud Star Acquisition	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D+)
6/23/2026	KLRS Kalaris Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
6/15/2026	KLRS Kalaris Therapeutics	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy
6/11/2026	ATRA Atara Biotherapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D) ➝ Sell (E+)

(Data available from 8/31/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ATRA Atara Biotherapeutics	$6.19M	14.55	$4.75 per share	1.89	($5.34) per share	-1.68
CVM Cel-Sci	N/A	N/A	N/A	N/A	$2.32 per share	N/A
DTSQ DT Cloud Star Acquisition	N/A	N/A	N/A	N/A	N/A	N/A
KLRS Kalaris Therapeutics	N/A	N/A	N/A	N/A	$4.21 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ATRA Atara Biotherapeutics	$32.69M	-$1.18	N/A	6.41	N/A	-269.42%	-79.12%	-73.01%	10/29/2026 (Estimated)
CVM Cel-Sci	-$25.41M	-$9.77	N/A	N/A	N/A	N/A	-250.83%	-125.06%	N/A
DTSQ DT Cloud Star Acquisition	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
KLRS Kalaris Therapeutics	-$43.44M	-$2.02	N/A	N/A	N/A	N/A	-71.71%	-42.95%	N/A

Latest CVM, DTSQ, KLRS, and ATRA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2026	Q3 2026	CVM Cel-Sci	N/A	-$0.47	N/A	-$0.47	N/A	N/A
8/12/2026	Q2 2026	ATRA Atara Biotherapeutics	-$0.3150	-$0.32	-$0.0050	-$0.32	$0.55 million	$0.63 million
8/11/2026	Q2 2026	KLRS Kalaris Therapeutics	-$0.50	-$0.48	+$0.02	-$0.48	N/A	N/A
8/3/2026	Q2 2026	DTSQ DT Cloud Star Acquisition	N/A	$0.0630	N/A	$0.0630	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ATRA Atara Biotherapeutics	N/A	N/A	N/A	N/A	N/A
CVM Cel-Sci	N/A	N/A	N/A	N/A	N/A
DTSQ DT Cloud Star Acquisition	N/A	N/A	N/A	N/A	N/A
KLRS Kalaris Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ATRA Atara Biotherapeutics	N/A	1.98	1.98
CVM Cel-Sci	0.35	1.48	1.42
DTSQ DT Cloud Star Acquisition	N/A	N/A	N/A
KLRS Kalaris Therapeutics	N/A	10.98	10.98

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ATRA Atara Biotherapeutics	70.90%
CVM Cel-Sci	12.08%
DTSQ DT Cloud Star Acquisition	N/A
KLRS Kalaris Therapeutics	66.05%

Insider Ownership

Company	Insider Ownership
ATRA Atara Biotherapeutics	41.20%
CVM Cel-Sci	14.06%
DTSQ DT Cloud Star Acquisition	52.88%
KLRS Kalaris Therapeutics	68.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ATRA Atara Biotherapeutics	330	10.04 million	5.90 million	No Data
CVM Cel-Sci	43	17.48 million	15.02 million	No Data
DTSQ DT Cloud Star Acquisition	N/A	8.90 million	4.19 million	N/A
KLRS Kalaris Therapeutics	110	23.81 million	7.59 million	N/A

CVM, DTSQ, KLRS, and ATRA Headlines

Recent News About These Companies

Kalaris to Present at Morgan Stanley 24th Annual Global Healthcare Conference

August 31 at 8:00 AM | globenewswire.com

Kalaris Therapeutics Inc. (NASDAQ:KLRS) Given Consensus Recommendation of "Moderate Buy" by Brokerages

August 31 at 4:28 AM | marketbeat.com

Analysts Offer Insights on Healthcare Companies: Airsculpt Technologies (AIRS), Biohaven Ltd. (BHVN) and Kalaris Therapeutics (KLRS)

August 15, 2026 | theglobeandmail.com

Analysts Offer Insights on Healthcare Companies: Mereo Biopharma Group Plc (MREO) and Kalaris Therapeutics (KLRS)

August 13, 2026 | theglobeandmail.com

Kalaris Therapeutics, Inc.: Kalaris Reports Second Quarter 2026 Financial Results and Provides Business Updates

August 11, 2026 | finanznachrichten.de

Kalaris Reports Second Quarter 2026 Financial Results and Provides Business Updates

August 11, 2026 | finance.yahoo.com

Kalaris Therapeutics (NASDAQ:KLRS) Announces Earnings Results

August 11, 2026 | marketbeat.com

Kalaris Therapeutics Inc. (NASDAQ:KLRS) Given Average Rating of "Moderate Buy" by Analysts

August 6, 2026 | marketbeat.com

Kalaris Therapeutics, Inc. (KLRS)

August 5, 2026 | finance.yahoo.com

Kalaris Therapeutics (NASDAQ:KLRS) Shares Up 15.4% – Here’s What Happened

August 4, 2026 | defenseworld.netD

Kalaris Therapeutics (NASDAQ:KLRS) Shares Up 15.4% - Here's What Happened

August 4, 2026 | marketbeat.com

KLRS: Abbott Cooper PLLC Announces Investigation on Behalf of Kalaris Therapeutics, Inc. (Formerly Allovir, Inc.) Stockholders

August 3, 2026 | globenewswire.com

Kalaris appoints Liisa Bayko as CFO

July 21, 2026 | msn.com

Kalaris Expands Leadership Team Appointing Liisa Bayko as Chief Financial Officer

July 20, 2026 | globenewswire.com

Kalaris Therapeutics Reports Positive TH103 Phase 1a SAD Results from Expanded Neovascular AMD Cohorts

July 17, 2026 | globenewswire.com

Kalaris Therapeutics (KLRS) Appoints Laurie Keating to Board

July 14, 2026 | finance.yahoo.com

Kalaris Appoints Laurie Keating to Board of Directors

July 6, 2026 | globenewswire.com

Kalaris Announces Upcoming Presentation of TH103 Phase 1a Clinical Data at American Society of Retina Specialists; Ph 1b/2 Clinical Trial Actively Enrolling

June 23, 2026 | globenewswire.com

Kalaris to Present at Clinical Trials at the Summit 2026

June 12, 2026 | finance.yahoo.com

Kalaris Therapeutics Stock Price History

May 30, 2026 | investing.com

Kalaris Therapeutics (NASDAQ:KLRS) Director Srinivas Akkaraju Acquires 244,300 Shares

May 23, 2026 | insidertrades.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CVM, DTSQ, KLRS, and ATRA Company Descriptions

Atara Biotherapeutics NASDAQ:ATRA

$8.98 -0.22 (-2.39%)

As of 03:07 PM Eastern

Atara Biotherapeutics, Inc. engages in the development of transformative therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma. Its CAR T immunotherapy pipeline products include ATA3219, currently in Phase 1 trials, as well as ATA3431, under preclinical trials for the treatment of B-cell malignancies and autoimmune diseases; and ATA188 that is in Phase 2 clinical trials to treat multiple sclerosis. The company has research collaboration agreements with Memorial Sloan Kettering Cancer Center, and Council of the Queensland Institute of Medical Research. Atara Biotherapeutics, Inc. was incorporated in 2012 and is headquartered in Thousand Oaks, California.

Cel-Sci NYSEAMERICAN:CVM

$1.59 +0.03 (+1.92%)

As of 03:20 PM Eastern

CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development of immune system therapy for the treatment of cancer and other diseases in the United States. The company's lead immunotherapy is Multikine, which has completed Phase 3 clinical trials for the potential treatment of certain head and neck cancers. It is also developing products based on its proprietary technology Ligand Epitope Antigen Presentation System (LEAPS) technology, a patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, parasitic infections, autoimmune conditions, allergies, transplantation rejections, and cancer. In addition, the company's product pipeline includes CEL-2000; CEL-4000; and CEL-5000, which are LEAPS-based product candidates in preclinical trials for the treatment of rheumatoid arthritis disease. CEL-SCI Corporation was incorporated in 1983 and is headquartered in Vienna, Virginia.

DT Cloud Star Acquisition NASDAQ:DTSQ

$11.35 +0.02 (+0.18%)

As of 03:10 PM Eastern

DT Cloud Star Acquisition Corporation focuses on effecting a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization, or similar business combination with one or more businesses or entities. The company was incorporated in 2022 and is based in Brooklyn, New York.

Kalaris Therapeutics NASDAQ:KLRS

$3.99 -0.04 (-0.99%)

As of 03:21 PM Eastern

Allovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. Its preclinical and clinical development product candidates include ALVR106 for the respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109 to treat SARS-CoV-2 and COVID-19; ALVR107 for treating hepatitis B; and ALVR108. The company was formerly known as ViraCyte, Inc. and changed its name to Allovir, Inc. in May 2019. Allovir, Inc. was founded in 2013 and is based in Waltham, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CVM, DTSQ, KLRS, and ATRA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CVM, DTSQ, KLRS, and ATRA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CVM, DTSQ, KLRS, and ATRA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

CVM, DTSQ, KLRS, and ATRA Company Descriptions

Atara Biotherapeutics NASDAQ:ATRA

Cel-Sci NYSEAMERICAN:CVM

DT Cloud Star Acquisition NASDAQ:DTSQ

Kalaris Therapeutics NASDAQ:KLRS

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CVM, DTSQ, KLRS, and ATRA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CVM, DTSQ, KLRS, and ATRA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CVM, DTSQ, KLRS, and ATRA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

CVM, DTSQ, KLRS, and ATRA Company Descriptions

Atara Biotherapeutics NASDAQ:ATRA

Cel-Sci NYSEAMERICAN:CVM

DT Cloud Star Acquisition NASDAQ:DTSQ

Kalaris Therapeutics NASDAQ:KLRS

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools